Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

GLYC

GlycoMimetics Inc

Sep 20 • 04:00PM ET

0.1648

Dollar change -0.0052
Percentage change -3.06	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.61	Insider Own	8.38%	Shs Outstand	64.39M	Perf Week	-3.06%
Market Cap	10.63M	Forward P/E	-	EPS next Y	-0.09	Insider Trans	-26.51%	Shs Float	59.08M	Perf Month	-10.92%
Income	-39.11M	PEG	-	EPS next Q	-0.11	Inst Own	35.46%	Short Float	3.27%	Perf Quarter	-35.95%
Sales	0.01M	P/S	1062.63	EPS this Y	12.93%	Inst Trans	-1.73%	Short Ratio	0.52	Perf Half Y	-94.28%
Book/sh	0.31	P/B	0.53	EPS next Y	82.18%	ROA	-90.71%	Short Interest	1.93M	Perf Year	-88.14%
Cash/sh	0.35	P/C	0.47	EPS next 5Y	-	ROE	-104.49%	52W Range	0.16 - 3.53	Perf YTD	-93.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.11%	ROI	-194.96%	52W High	-95.33%	Beta	2.05
Dividend TTM	-	Quick Ratio	5.48	Sales past 5Y	-53.76%	Gross Margin	-3102.77%	52W Low	6.32%	ATR (14)	0.01
Dividend Ex-Date	-	Current Ratio	5.48	EPS Y/Y TTM	7.48%	Oper. Margin	-408772.17%	RSI (14)	41.58	Volatility	6.81% 7.38%
Employees	35	Debt/Eq	0.02	Sales Y/Y TTM	-86.67%	Profit Margin	-391135.91%	Recom	3.00	Target Price	0.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-21.87%	Payout	-	Rel Volume	0.11	Prev Close	0.17
Sales Surprise	-	EPS Surprise	7.46%	Sales Q/Q	-	Earnings	Aug 01	Avg Volume	3.71M	Price	0.16
SMA20	-2.94%	SMA50	-20.22%	SMA200	-88.94%	Trades		Volume	395,659	Change	-3.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
04:01PM	Loading…
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Loading…
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
12:00PM	Loading…
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
07:17AM	Daily Vickers Top Buyers & Sellers for 02/24/2023 (Argus Research)
Feb-16-23 08:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.41%
Feb-15-23 08:00AM	GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee (Business Wire) -62.47%
Feb-14-23 06:23AM	Daily Vickers Top Buyers & Sellers for 02/14/2023 (Argus Research) +7.14%
Feb-06-23 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-22-23 07:30AM	This Small Pharma Company Could Develop Into a Nice Trade (TheStreet.com)
07:24AM	GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit (Simply Wall St.)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-28-22 06:58AM	Daily Vickers Top Buyers & Sellers for 12/28/2022 (Argus Research) +19.20%
Dec-26-22 07:14AM	Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-19-22 09:40AM	Is Axonics (AXNX) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-12-22 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting (Business Wire)
Dec-02-22 01:18PM	Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18% (Simply Wall St.) +7.01%
09:40AM	Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-23-22 09:55AM	After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright (Zacks)
Nov-16-22 09:40AM	Are Medical Stocks Lagging Axonics (AXNX) This Year? (Zacks) +9.41%
Nov-12-22 07:14AM	GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021) (Simply Wall St.)
Nov-10-22 09:12AM	Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k (Simply Wall St.) +19.48%
Nov-09-22 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022 (Business Wire) +19.32%
Nov-08-22 04:05PM	GlycoMimetics to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-03-22 09:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting (Business Wire)

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Invus Public Equities, L.P.	10% Owner	Aug 08 '24	Sale	0.19	260,873	50,009	6,317,565	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 07 '24	Sale	0.18	61,488	11,197	6,578,438	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 05 '24	Sale	0.19	164,523	30,996	6,695,658	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 06 '24	Sale	0.18	55,732	10,188	6,639,926	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 02 '24	Sale	0.20	286,200	57,354	6,860,181	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Aug 01 '24	Sale	0.22	63,564	13,743	7,146,381	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Jul 30 '24	Sale	0.22	756,835	167,185	7,209,945	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 29 '24	Sale	0.24	363,949	85,637	7,966,780	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 26 '24	Sale	0.24	258,335	62,440	8,330,729	Jul 30 05:16 PM
Rock Edwin	Chief Medical Officer	Jun 20 '24	Buy	0.25	190,000	48,108	565,403	Jun 24 04:29 PM
Rock Edwin	Chief Medical Officer	Jun 21 '24	Buy	0.27	115,000	30,716	680,403	Jun 24 04:29 PM
Hahn Brian M.	SVP Finance, CFO	Jun 18 '24	Buy	0.25	17,500	4,335	70,643	Jun 20 04:15 PM
Rock Edwin	Chief Medical Officer	Sep 21 '23	Buy	1.38	35,000	48,300	345,000	Sep 25 04:21 PM
Rock Edwin	Chief Medical Officer	Sep 22 '23	Buy	1.38	30,403	41,956	375,403	Sep 25 04:21 PM

Open in Screener

SRRK

Scholar Rock Holding Corp

Sep 20 • 04:00PM ET

9.39

Dollar change +0.88
Percentage change 10.34	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

SRRK Scholar Rock Holding Corp daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.33	Insider Own	18.31%	Shs Outstand	75.98M	Perf Week	9.57%
Market Cap	751.48M	Forward P/E	-	EPS next Y	-1.98	Insider Trans	-0.16%	Shs Float	65.38M	Perf Month	1.40%
Income	-203.85M	PEG	-	EPS next Q	-0.58	Inst Own	95.23%	Short Float	24.33%	Perf Quarter	11.12%
Sales	0.00M	P/S	-	EPS this Y	-13.00%	Inst Trans	-2.45%	Short Ratio	20.34	Perf Half Y	-45.41%
Book/sh	1.67	P/B	5.62	EPS next Y	11.78%	ROA	-79.66%	Short Interest	15.91M	Perf Year	34.91%
Cash/sh	2.38	P/C	3.94	EPS next 5Y	-	ROE	-121.29%	52W Range	6.03 - 21.17	Perf YTD	-50.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.79%	ROI	-105.14%	52W High	-55.64%	Beta	0.83
Dividend TTM	-	Quick Ratio	6.04	Sales past 5Y	-5.25%	Gross Margin	-	52W Low	55.72%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	6.04	EPS Y/Y TTM	-2.48%	Oper. Margin	0.00%	RSI (14)	57.67	Volatility	8.80% 7.17%
Employees	150	Debt/Eq	0.51	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	27.86
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-27.65%	Payout	-	Rel Volume	2.67	Prev Close	8.51
Sales Surprise	-	EPS Surprise	-1.63%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	782.19K	Price	9.39
SMA20	7.30%	SMA50	5.27%	SMA200	-27.10%	Trades		Volume	2,086,151	Change	10.34%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-04-24 08:00AM	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Business Wire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
08:00AM	Loading…
Aug-29-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-15-24 04:32AM	Scholar Rocks apitegromab shows promise for non-ambulatory SMA (Clinical Trials Arena)
Aug-09-24 05:05AM	Q2 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-24 07:00AM	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Jul-23-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire)
Jul-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-24 06:42PM	Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 07:00AM	Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal (Business Wire)
04:15PM	Loading…
Jun-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 04:00PM	Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting (Business Wire)
May-28-24 08:00AM	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-22-24 07:00AM	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Business Wire)
May-20-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
May-17-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.78%
May-14-24 08:00AM	Scholar Rock to Host Investor Day on May 22, 2024 (Business Wire)
May-07-24 01:53PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 (InvestorPlace)
10:19AM	Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss (MT Newswires)
08:52AM	Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
07:00AM	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Apr-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
Mar-20-24 05:31AM	Scholar Rock Holding Corp Reports Full Year 2023 Financial Results (GuruFocus.com) +8.58%
Mar-19-24 10:52PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 (InvestorPlace) +14.77%
07:00AM	Loading…
07:00AM	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Business Wire)
Mar-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.65%
08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Feb-28-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.42%
Feb-15-24 08:00AM	Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer (Business Wire)
Feb-06-24 08:00AM	Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management (Business Wire)
Jan-25-24 08:00AM	Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia (Business Wire)
Jan-23-24 08:00AM	Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity (Business Wire)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal)
Jan-18-24 05:01PM	Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com) -5.10%
Jan-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 08:00AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 (Business Wire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace) -6.91%
Dec-30-23 07:01PM	Insider Edward Myles Sells 12,459 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Dec-19-23 08:00AM	Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.29%
Dec-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Dec-10-23 09:05AM	Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Nov-17-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-23 12:32PM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:14AM	Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial Results (GuruFocus.com)
07:15AM	Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress (Business Wire)
Nov-06-23 09:55AM	Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High? (Zacks)
Nov-03-23 11:52PM	Insider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
04:00PM	Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability (Business Wire)
Nov-02-23 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK) (Zacks)
Oct-24-23 12:00PM	All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy (Zacks)
Oct-23-23 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (Business Wire)
Oct-19-23 09:55AM	Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet (Zacks)
08:00AM	Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -13.56%
Oct-16-23 04:15PM	Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) +5.36% +5.33%
Oct-13-23 12:45PM	Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering (Zacks)
Oct-12-23 04:17PM	Why Scholar Rock Holding Stock Soared Today (Motley Fool) +17.66%
Oct-11-23 08:57PM	Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
05:05PM	Scholar Rock Announces Proposed Public Offering of Common Stock (Business Wire)
04:44PM	Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders (Business Wire)
Sep-19-23 08:00AM	Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial (Business Wire) +10.74%
Sep-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-23 09:55AM	Wall Street Analysts Believe Scholar Rock Holding Corporation (SRRK) Could Rally 264.53%: Here's is How to Trade (Zacks)
Aug-18-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Aug-09-23 04:15PM	Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress (Business Wire) +11.33%
Aug-02-23 10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks) +6.86%
Jul-13-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-23 11:00AM	New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy (Business Wire) +10.07%
Jun-15-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-01-23 04:05PM	Scholar Rock to Present at the Jefferies Healthcare Conference (Business Wire) +6.45%
May-10-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 07:30AM	Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress (Business Wire) +5.98%
May-08-23 08:00AM	Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference (Business Wire)
Apr-17-23 12:57PM	Scholar Rock Holding Corporation's (NASDAQ:SRRK) Business Is Trailing The Industry But Its Shares Aren't (Simply Wall St.)
Apr-12-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-10-23 04:05PM	Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors (Business Wire)
Mar-15-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-07-23 07:00AM	Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress (Business Wire) +6.55%
Mar-01-23 08:00AM	Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-27-23 08:00AM	Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-17-23 08:00AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-11-23 07:23AM	Shareholders in Scholar Rock Holding (NASDAQ:SRRK) have lost 43%, as stock drops 13% this past week (Simply Wall St.)
Feb-06-23 08:00AM	Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer (Business Wire)
Jan-09-23 08:00AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2023 (Business Wire)
Jan-03-23 08:00AM	Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +5.86%
Nov-16-22 06:04AM	Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021) (Simply Wall St.)
Nov-15-22 08:00AM	Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.78%
Nov-14-22 08:00AM	Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress (Business Wire)
Nov-10-22 09:00AM	Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy (Business Wire)
Nov-09-22 08:00AM	Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer (Business Wire) -5.90%
Nov-08-22 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Oct-22-22 07:00AM	New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA (Business Wire)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '24	Sale	8.58	1,936	16,611	142,768	Sep 19 08:15 AM
Parlavecchio Caryn	CHRO	Aug 16 '24	Sale	9.33	1,451	13,538	151,988	Aug 19 05:00 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 17 '24	Sale	8.98	2,315	20,800	144,704	Jun 18 05:56 PM
Parlavecchio Caryn	CHRO	Jun 17 '24	Sale	8.98	4,305	38,680	153,439	Jun 18 05:55 PM
Myles Edward H	COO & CFO	Jun 17 '24	Sale	8.98	9,458	84,978	201,518	Jun 18 05:54 PM
Ho Junlin	GENERAL COUNSEL	Jun 17 '24	Sale	8.98	4,695	42,183	204,076	Jun 18 05:53 PM
Myles Edward H	COO & CFO	Feb 16 '24	Sale	15.74	4,744	74,686	210,976	Feb 21 06:13 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 16 '24	Sale	15.74	2,512	39,547	147,019	Feb 20 04:58 PM
Parlavecchio Caryn	CHRO	Feb 16 '24	Sale	15.74	3,751	59,053	157,744	Feb 20 04:52 PM
Ho Junlin	GENERAL COUNSEL	Feb 16 '24	Sale	15.74	3,489	54,928	208,771	Feb 20 04:48 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.74	11,614	182,842	352,671	Feb 20 04:46 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Jan 16 '24	Sale	15.93	2,002	31,889	78,816	Jan 18 04:11 PM
Parlavecchio Caryn	CHRO	Jan 16 '24	Sale	15.93	2,849	45,381	114,350	Jan 18 04:08 PM
Myles Edward H	COO & CFO	Jan 16 '24	Sale	15.93	6,634	105,670	162,150	Jan 18 04:07 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '24	Sale	15.93	4,186	66,677	154,405	Jan 18 04:05 PM
Myles Edward H	COO & CFO	Dec 29 '23	Option Exercise	4.86	12,459	60,551	181,243	Dec 29 07:13 PM
Myles Edward H	COO & CFO	Dec 29 '23	Sale	18.83	12,459	234,633	168,784	Dec 29 07:13 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Dec 14 '23	Option Exercise	10.00	8,437	84,370	105,480	Dec 15 04:13 PM
Qatanani Mo	SVP AND HEAD OF RESEARCH	Dec 14 '23	Sale	18.18	24,662	448,444	80,818	Dec 15 04:13 PM
Myles Edward H	COO & CFO	Dec 07 '23	Option Exercise	4.86	24,914	121,082	193,698	Dec 08 04:12 PM
Myles Edward H	COO & CFO	Dec 07 '23	Sale	17.53	24,914	436,820	168,784	Dec 08 04:12 PM
Myles Edward H	COO & CFO	Nov 02 '23	Sale	12.51	35,007	438,039	168,784	Nov 03 06:11 PM
AKKARAJU SRINIVAS	Director	Oct 16 '23	Buy	6.85	2,189,781	15,000,000	6,788,609	Oct 18 05:46 PM
Samsara BioCapital GP, LLC	10% Owner	Oct 16 '23	Buy	6.85	2,189,781	15,000,000	6,788,609	Oct 18 05:44 PM
Invus Public Equities, L.P.	10% Owner	Oct 12 '23	Buy	6.86	2,199,931	15,086,736	11,259,438	Oct 16 05:46 PM

GLYC

GlycoMimetics Inc

SRRK

Scholar Rock Holding Corp

Upgrade your FINVIZ experience